Your browser doesn't support javascript.
loading
Nuclear Her2 contributes to paclitaxel resistance in breast cancer cells.
Luo, Bo; Wu, Xin-Hong; Feng, Yao-Jun; Zheng, Hong-Mei; Zhang, Qu; Liang, Xin-Jun; Huang, Ding-Feng; Xu, Juan.
Affiliation
  • Luo B; Department of Radiotherapy Center.
  • Wu XH; Department of Breast Cancer Center.
  • Feng YJ; Department of Breast Cancer Center.
  • Zheng HM; Department of Breast Cancer Center.
  • Zhang Q; Department of Radiotherapy Center.
  • Liang XJ; Department of Abdominal Tumor, Hubei Cancer Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
  • Huang DF; Department of Radiotherapy Center.
  • Xu J; Department of Breast Cancer Center.
Anticancer Drugs ; 32(7): 709-716, 2021 08 01.
Article in En | MEDLINE | ID: mdl-33587352
Subject(s)
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Breast Neoplasms / Paclitaxel / Receptor, ErbB-2 / Drug Resistance, Neoplasm Limits: Female / Humans Language: En Journal: Anticancer Drugs Journal subject: ANTINEOPLASICOS Year: 2021 Document type: Article
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Breast Neoplasms / Paclitaxel / Receptor, ErbB-2 / Drug Resistance, Neoplasm Limits: Female / Humans Language: En Journal: Anticancer Drugs Journal subject: ANTINEOPLASICOS Year: 2021 Document type: Article